Courtney M Keller1, Allyson L Spence2, Misty W Stevens3, S Michael Owens3,4, Glenn F Guerin5, Nicholas E Goeders5. 1. Department of Pharmacology, Toxicology & Neuroscience, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71130, USA. ckell1@lsuhsc.edu. 2. Regis University School of Pharmacy, 3333 Regis Boulevard, Denver, CO, 80221, USA. 3. InterveXion Therapeutics, LLC, 4301 W. Markham St. #831, Little Rock, AR, 72205, USA. 4. Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, 4301 W. Markham St. #611, Little Rock, AR, 72205, USA. 5. Department of Pharmacology, Toxicology & Neuroscience, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71130, USA.
Abstract
RATIONALE: Vaccines have been developed as a potential treatment for methamphetamine (meth) use disorder (MUD). Immunization with the meth vaccine IXT-v100 has previously been shown to elicit antibodies with high affinity for meth and thus may be an effective treatment for MUD. OBJECTIVES: These studies were designed to determine the efficacy of IXT-v100 on meth-taking and meth-seeking behaviors in rats. METHODS: In the acquisition and maintenance study, male and female rats were trained to self-administer meth (0.06 mg/kg/infusion) over an 8-week period following vaccination. In the last 4 weeks, the dose of meth was increased or decreased each week. To assess meth-seeking behavior, the meth-primed reactivity model was used. Rats were trained to self-administer meth for 5 weeks, followed by a 5-week or 11-week forced abstinence period during which the animals were vaccinated. Rats were then placed back into the self-administration chamber immediately after being injected with meth (1 mg/kg, i.p.) but did not receive meth during the session. Responses were recorded and used as a measure of meth seeking. RESULTS: Results from the acquisition and maintenance study in Wistar rats show that vaccination with IXT-v100 adjuvanted with glucopyranosyl lipid A stable emulsion decreases the percentage of animals that will self-administer a moderate level of meth. In the meth-primed reactivity studies, results from males showed that vaccination significantly attenuates meth-seeking behavior. CONCLUSION: Together, these results suggest vaccination with IXT-v100 may be effective at decreasing meth-taking and meth-seeking behaviors in humans suffering with MUD.
RATIONALE: Vaccines have been developed as a potential treatment for methamphetamine (meth) use disorder (MUD). Immunization with the meth vaccine IXT-v100 has previously been shown to elicit antibodies with high affinity for meth and thus may be an effective treatment for MUD. OBJECTIVES: These studies were designed to determine the efficacy of IXT-v100 on meth-taking and meth-seeking behaviors in rats. METHODS: In the acquisition and maintenance study, male and female rats were trained to self-administer meth (0.06 mg/kg/infusion) over an 8-week period following vaccination. In the last 4 weeks, the dose of meth was increased or decreased each week. To assess meth-seeking behavior, the meth-primed reactivity model was used. Rats were trained to self-administer meth for 5 weeks, followed by a 5-week or 11-week forced abstinence period during which the animals were vaccinated. Rats were then placed back into the self-administration chamber immediately after being injected with meth (1 mg/kg, i.p.) but did not receive meth during the session. Responses were recorded and used as a measure of meth seeking. RESULTS: Results from the acquisition and maintenance study in Wistar rats show that vaccination with IXT-v100 adjuvanted with glucopyranosyl lipid A stable emulsion decreases the percentage of animals that will self-administer a moderate level of meth. In the meth-primed reactivity studies, results from males showed that vaccination significantly attenuates meth-seeking behavior. CONCLUSION: Together, these results suggest vaccination with IXT-v100 may be effective at decreasing meth-taking and meth-seeking behaviors in humans suffering with MUD.
Authors: W C Drevets; C Gautier; J C Price; D J Kupfer; P E Kinahan; A A Grace; J L Price; C A Mathis Journal: Biol Psychiatry Date: 2001-01-15 Impact factor: 13.382
Authors: V Villemagne; J Yuan; D F Wong; R F Dannals; G Hatzidimitriou; W B Mathews; H T Ravert; J Musachio; U D McCann; G A Ricaurte Journal: J Neurosci Date: 1998-01-01 Impact factor: 6.167
Authors: J D Nguyen; P T Bremer; C S Hwang; S A Vandewater; K C Collins; K M Creehan; K D Janda; M A Taffe Journal: Drug Alcohol Depend Date: 2017-04-14 Impact factor: 4.492
Authors: Serena Tonstad; Eli Heggen; Hans Giljam; Per-Åke Lagerbäck; Philip Tønnesen; Lena Degling Wikingsson; Nina Lindblom; Sabina de Villiers; Torgny H Svensson; Karl-Olov Fagerström Journal: Nicotine Tob Res Date: 2013-03-07 Impact factor: 4.244
Authors: B S Fox; K M Kantak; M A Edwards; K M Black; B K Bollinger; A J Botka; T L French; T L Thompson; V C Schad; J L Greenstein; M L Gefter; M A Exley; P A Swain; T J Briner Journal: Nat Med Date: 1996-10 Impact factor: 53.440
Authors: Marek Schwendt; Angelica Rocha; Ronald E See; Alejandra M Pacchioni; Jacqueline F McGinty; Peter W Kalivas Journal: J Pharmacol Exp Ther Date: 2009-07-31 Impact factor: 4.030